key: cord-1023710-3hojib0u authors: Warrier, Sudha; S, Mohana Sundaram; Varier, Lavanya; Balasubramanian, Ananthakrishnan title: Stalling SARS-CoV2 infection with stem cells: can regenerating perinatal tissue mesenchymal stem cells offer a multi-tiered therapeutic approach to COVID-19? date: 2021-12-06 journal: Placenta DOI: 10.1016/j.placenta.2021.12.005 sha: 4f6a767ba7add79b6afe5ec2913ab65c99956277 doc_id: 1023710 cord_uid: 3hojib0u The emergence of COVID-19 has created a major health crisis across the globe. Invasion of SARS-CoV-2 into the lungs causes acute respiratory distress syndrome (ARDS) that result in the damage of lung alveolar epithelial cells. Currently, there is no standard treatment available to treat the disease and the resultant lung scarring is irreversible even after recovery. This has prompted researchers across the globe to focus on developing new therapeutics and vaccines for the treatment and prevention of COVID-19. Mesenchymal stem cells (MSCs) have emerged as an efficient drug screening platform and MSC-derived organoids has found applications in disease modeling and drug discovery. Perinatal tissue derived MSC based cell therapies have been explored in the treatment of various disease conditions including ARDS because of their enhanced regenerative and immunomodulatory properties. The multi-utility properties of MSCs have been described in this review wherein we discuss the potential use of MSC-derived lung organoids in screening of novel therapeutic compounds for COVID-19 and also in disease modeling to better understand the pathogenesis of the disease. This article also summarizes the rationale behind the development of MSC-based cell- and cell-free therapies and vaccines for COVID-19 with a focus on the current progress in this area. With the pandemic raging, an important necessity is to develop novel treatment strategies which will not only alleviate the disease symptoms but also avoid any off-target effects which could further increase post infection sequelae. Naturally occurring mesenchymal stem cells could be the magic bullet which fulfil these criteria. with respect to COVID-19. Previously, in the case of Zika virus (ZIKV), a virus that mainly targets 147 developing foetus and causes microcephaly, brain organoids have been developed to study its 148 pathogenesis. As stem cell-derived brain organoids are similar to the foetal brain, they have been 149 exploited to study ZIKV infection. It was identified that early-stage organoids are particularly Organ-on-a-chip is an emerging technology that can effectively mimic in vivo conditions. They Mesenchymal stem cells in health and disease Concise review: the surface markers and identity of 397 human mesenchymal stem cells Mesenchymal stromal cells: tissue repair and immune modulation Mesenchymal stem cell mediates cardiac repair through 401 autocrine, paracrine and endocrine axes Stem Cells for Treatment of Musculoskeletal Conditions-Orthopaedic/Sports 403 Medicine Applications Differentiation 406 of human mesenchymal stem cells towards neuronal lineage: clinical trials in nervous system disorders Novel therapy for insulin-dependent 409 diabetes mellitus: infusion of in vitro-generated insulin-secreting cells Comparison of conventional and advanced in vitro models in the toxicity testing of 412 nanoparticles, Artificial cells, nanomedicine, and biotechnology Crabtree effect in ascites hepatoma cells Circumventing the Crabtree effect: 416 replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants Stem cells as a novel tool for drug 419 screening and treatment of degenerative diseases Human pluripotent stem cell-based organoids and cell platforms for modelling 422 SARS-CoV-2 infection and drug discovery iPSC-derived MSC therapy induces immune tolerance and supports long-term graft survival in 425 mouse orthotopic tracheal transplants Generation and applications of induced pluripotent stem cell-derived mesenchymal 427 stem cells Receptor recognition by the novel coronavirus from 429 Wuhan: an analysis based on decade-long structural studies of SARS coronavirus SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a 433 clinically proven protease inhibitor Pathogenesis of COVID-19 from a cell biology perspective SARS-CoV replicates in primary human alveolar type II cell cultures 437 but not in type I-like cells Innate 439 immune response of human alveolar type II cells infected with severe acute respiratory syndrome-440 coronavirus Acute respiratory distress syndrome: an update and review Cell-based Therapy for Chronic Obstructive Pulmonary Disease. Rebuilding the Lung The development of a novel cancer immunotherapeutic platform using tumor-targeting 447 mesenchymal stem cells and a protein vaccine Mesenchymal stem cells as a novel vaccine platform Engineered human mesenchymal stem cells as new vaccine platform for COVID-452 Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic 455 review and meta-analysis Pulmonary fibrosis in COVID-19 survivors: Predictive 457 factors and risk reduction strategies Its Impact on Organs and Potential Treatment by QTY Code-Designed Detergent-Free Chemokine 460 Receptors Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China The role of mesenchymal stromal cells in immune modulation of 466 COVID-19: focus on cytokine storm Current status of mesenchymal stem cell therapy 468 for immune/inflammatory lung disorders: gleaning insights for possible use in COVID-19 Zika virus impairs growth in human neurospheres and brain organoids Zika Virus Depletes Neural 474 Progenitors in Human Cerebral Organoids through Activation of the Innate Immune Receptor TLR3 Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure Bone marrow mesenchymal stem 482 cells can differentiate into type II alveolar epithelial cells in vitro 485 Identification of candidate COVID-19 therapeutics using hPSC-derived lung organoids Identification of SARS-CoV-2 inhibitors using lung and colonic 490 organoids Androgen 494 Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms Human lung stem cell-based alveolospheres provide insights into SARS-CoV-2-498 mediated interferon responses and pneumocyte dysfunction Adult Stem Cell-derived Complete Lung Organoid 502 Models Emulate Lung Disease in COVID-19, bioRxiv : the preprint server for biology An organoid-derived 506 bronchioalveolar model for SARS-CoV-2 infection of human alveolar type II-like cells Human embryonic lung epithelial tips are multipotent 510 progenitors that can be expanded in vitro as long-term self-renewing organoids Drug inhibition of SARS-CoV-2 replication in human pluripotent stem cell-derived 513 intestinal organoids Toll-like 515 receptors on human mesenchymal stem cells drive their migration and immunomodulating responses Coronaviruses: from common colds to severe acute respiratory syndrome, The Pediatric 518 infectious disease journal Strategies to enhance mesenchymal stem cell-based therapies for acute respiratory 520 distress syndrome Bone marrow-523 derived mesenchymal stem cells attenuate pulmonary inflammation and lung damage caused by highly 524 pathogenic avian influenza A/H5N1 virus in BALB/c mice Human mesenchymal stromal cells reduce 527 influenza A H5N1-associated acute lung injury in vitro and in vivo Therapeutic 530 Implications of Human Umbilical Cord Mesenchymal Stromal Cells in Attenuating Influenza A (H5N1) Virus-Associated Acute Lung Injury Effects of Wharton's jelly-derived mesenchymal stem cells on chronic 533 obstructive pulmonary disease Mesenchymal stem cells for 535 bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial Mesenchymal stem cells: mechanisms of potential therapeutic 538 benefit in ARDS and sepsis Overexpressing 540 p130/E2F4 in mesenchymal stem cells facilitates the repair of injured alveolar epithelial cells in LPS-541 induced ARDS mice Synergism of MSC-secreted HGF and VEGF in 543 stabilising endothelial barrier function upon lipopolysaccharide stimulation via the Rac1 pathway Derived MSCs in Repairing Acute Lung Injury Current status of cell-based 548 therapies for respiratory virus infections: applicability to COVID-19 The pros and cons of mesenchymal stem cell-based therapies Stem cell therapy for COVID-19: Possibilities and challenges Challenges and translational considerations of mesenchymal 555 stem/stromal cell therapy for Parkinson's disease, npj Effect of human 557 umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a 558 randomized, double-blind, placebo-controlled phase 2 trial Safety and feasibility of 561 umbilical cord mesenchymal stem cells in patients with COVID-19 pneumonia: A pilot study Administration of umbilical cord mesenchymal stem 564 cells in patients with severe COVID-19 pneumonia Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients 569 with COVID-19 Pneumonia IFITM-family proteins: the cell's first line of antiviral 571 defense Mesenchymal Stromal Cells in Viral Infections: Implications for COVID-19 Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between 577 H9N2 and H5N1 human isolates Characteristics of human infection with avian influenza viruses and 580 development of new antiviral agents Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a 583 phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor Mesenchymal stromal cell treatment 586 prevents H9N2 avian influenza virus-induced acute lung injury in mice Encapsulated human mesenchymal stem 589 cells (eMSCs) as a novel anti-cancer agent targeting breast cancer stem cells: Development of 3D primed 590 therapeutic MSCs Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth 5p-Containing Exosomes Treatment Attenuates Acute Myocardial Infarction-Induced Myocardial Damage, 596 Molecular therapy Therapeutic potential of mesenchymal 598 stem cell-derived microvesicles Exosomes derived from mesenchymal stem cells, International journal of 600 molecular sciences Re-engineering extracellular vesicles as smart nanoscale 602 therapeutics Exosome secretion: molecular mechanisms and roles in 604 immune responses Exosomes and the emerging field of exosome-based 606 gene therapy Exosome-mediated transfer of 608 mRNAs and microRNAs is a novel mechanism of genetic exchange between cells ExoCarta 2012: database of exosomal proteins, 611 RNA and lipids Mesenchymal stem cells secrete 613 immunologically active exosomes Microvesicles: ubiquitous contributors to infection and immunity The multifaceted exosome: biogenesis, role in normal and aberrant 617 cellular function, and frontiers for pharmacological and biomarker opportunities HCV transmission by hepatic exosomes establishes a productive infection Cells infected with herpes simplex virus 1 export to uninfected cells 622 exosomes containing STING, viral mRNAs, and microRNAs TGF-β suppression of HBV RNA through AID-dependent recruitment of an RNA exosome 626 complex Exosomes in human semen restrict HIV-1 transmission by 628 vaginal cells and block intravaginal replication of LP-BM5 murine AIDS virus complex Mesenchymal stem cell: an efficient 631 mass producer of exosomes for drug delivery Exosome and exosomal microRNA: trafficking, sorting, 633 and function Exosome-delivered microRNAs modulate the inflammatory response 636 to endotoxin Exosomes derived from mineralizing osteoblasts promote ST2 638 cell osteogenic differentiation by alteration of microRNA expression Exosomes from mesenchymal stem/stromal cells: a new therapeutic 640 paradigm Mesenchymal stem cell-derived exosomes: new 642 opportunity in cell-free therapy Exosomal microRNAs derived from 644 umbilical mesenchymal stem cells inhibit hepatitis C virus infection Nebulization therapy with 647 umbilical cord mesenchymal stem cell-derived exosomes for COVID-19 pneumonia Exosomes derived from bone 649 marrow mesenchymal stem cells as treatment for severe COVID-19 Lung organoids 654 expressing viral target proteins such as ACE2 generated by the differentiation of MSCs isolated 655 from perinatal tissues are excellent model systems in novel drug screening and to study host-virus 656 Exosomes isolated from 658 mesenchymal stem cells (MSCs) can be delivered via intranasal route that will act against SARS-659 CoV-2 through immunomodulation and inhibiting viral replication. of stem cell-based cell-and cell-free therapies and vaccines for COVID  Naturally occurring perinatal tissue stem cells could be the magic bullet for COVID therapy and drug screening J o u r n a l P r e -p r o o f Authors declare no conflict of interest for the article titled-'Stalling SARS-CoV2 infection with stem cells: can regenerating perinatal tissue mesenchymal stem cells offer a multitiered therapeutic approach to COVID-19?'.